1. Edo Agustian Indonesian Drug Users Network kornas@pkni.org Experiencing HCV Infection – the treatment, the reality and the possibilities for Cure

2. Outline of Presentation Overview of hepatitis C among people who inject drugs in Indonesia Indonesia’s national response Barriers to testing and treatment access Advocacy and community engagement

3. Viral Hepatitis in Indonesia

4. The national response to the prevention, treatment and management of hepatitis C among people who inject drugs Late response, fragmented Indonesia does not conduct routine national surveillance There is no national clinical guideline for diagnosis, treatment and care for HCV The Ministry of Health first established a national program focused on viral hepatitis in 2011, under the Sub Directorate for Gastrointestinal Infections and Diarrheal Diseases.

6. Barriers to get test and treatment for Hep C in Indonesia: Basic principles of Human Rights are still neglected Lack of knowledge and awareness among community, general population and health worker PUD’s are excluded from Indonesian National Insurance Health Scheme Hep C in Harm Reduction comprehensive package is still neglected (Monitoring Quality of Harm Reduction Services by community perspective) Stigma (Treatment Study for co-infected HCV/HIV still excluded active DU and their under MMT)

7. Advocacy and community engagement Since 2011, PKNI has worked with drug users, policy-makers, and service providers to raise awareness about Hep C and ensure that the community is meaningfully involved in the national response. Highlights include: o In 2011 conducted study : Barriers to Hep C Diagnosis, Management and Treatment among PWID in 4 Asian countries o Training of harm reduction service providers across 9 provinces o Policy briefing on Hep C o Collaboration with Indonesian Liver Researchers Association and Ministry of health on public Hep C campaign o Involved in developing National Guideline for Hep C Care, Support and Treatment with MoH in 2014 o Hepatitis C Community Task Force to input in MoH planning o Treatment price reductions and pharma advocacy